发布求助
文献互助 智能选刊 最新文献

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy最新文献

筛选
英文 中文
Comparative Effectiveness of Taxane‐Containing Regimens for Treatment of HER2‐Negative Metastatic Breast Cancer: A Network Meta‐analysis 含紫杉烷方案治疗HER2阴性转移性乳腺癌的比较疗效:网络Meta分析
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-12-01 DOI: 10.1002/phar.2344
Lei Dong, L. Zhu, Bao-jie Xie, Ji-bin Li, Tao Ding, Yun-fa Jiang, Zhong-Ning Zhu
{"title":"Comparative Effectiveness of Taxane‐Containing Regimens for Treatment of HER2‐Negative Metastatic Breast Cancer: A Network Meta‐analysis","authors":"Lei Dong, L. Zhu, Bao-jie Xie, Ji-bin Li, Tao Ding, Yun-fa Jiang, Zhong-Ning Zhu","doi":"10.1002/phar.2344","DOIUrl":"https://doi.org/10.1002/phar.2344","url":null,"abstract":"To compare the effectiveness of different taxane‐containing regimens and to identify the best strategy for the treatment of human epidermal growth factor receptor 2 (HER2)‐negative metastatic breast cancer (MBC).","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87184941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer 恩杂鲁胺及其主要代谢物在真实世界转移性去势抵抗性前列腺癌患者队列中的暴露反应评估
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-12-01 DOI: 10.1002/phar.2339
M. Nuland, A. Bergman, H. Rosing, N. Vries, A. Huitema, J. Beijnen
{"title":"Exposure‐Response Assessment of Enzalutamide and Its Major Metabolites in a Real‐World Cohort of Patients with Metastatic Castration‐Resistant Prostate Cancer","authors":"M. Nuland, A. Bergman, H. Rosing, N. Vries, A. Huitema, J. Beijnen","doi":"10.1002/phar.2339","DOIUrl":"https://doi.org/10.1002/phar.2339","url":null,"abstract":"Enzalutamide is an oral agent for the treatment of metastatic castration‐resistant prostate cancer (mCRPC); N‐desmethyl enzalutamide is its active metabolite, which has clinically relevant anti‐androgen capacities similar to enzalutamide, and carboxylic acid enzalutamide is an inactive metabolite. The aim of our study was to investigate the relationship between enzalutamide and N‐desmethyl enzalutamide exposure and treatment response in a real‐world cohort of patients with mCRPC.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79019867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study 比伐鲁定延长亚治疗抗凝治疗的危险因素和预后:一项回顾性队列研究
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-12-01 DOI: 10.1002/phar.2335
Libby A Orzel, Erik E. Abel, D. Blais, Tzu‐Fei Wang, K. Porter, P. Burcham
{"title":"Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study","authors":"Libby A Orzel, Erik E. Abel, D. Blais, Tzu‐Fei Wang, K. Porter, P. Burcham","doi":"10.1002/phar.2335","DOIUrl":"https://doi.org/10.1002/phar.2335","url":null,"abstract":"Bivalirudin, a direct thrombin inhibitor, is a treatment option for the management of heparin‐induced thrombocytopenia (HIT) and other coagulation disorders. To date, no published studies have identified patients at risk for or the consequence of subtherapeutic bivalirudin therapy.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80202425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study CYP2C19基因型和药物相互作用对伏立康唑血药浓度的影响:一项西班牙药物遗传-药代动力学前瞻性多中心研究
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-11-29 DOI: 10.1002/phar.2351
S. Blanco Dorado, O. Maroñas, Ana Latorre-Pellicer, Teresa Rodríguez Jato, Ana López-Vizcaíno, Áurea María Gómez Márquez, B. Bardán García, Dolores Belles Medall, G. Barbeito Castiñeiras, M. L. Pérez Del Molino Bernal, M. Campos‐Toimil, F. O. Otero Espinar, Andrés Blanco Hortas, G. Durán Piñeiro, I. Zarra Ferro, Á. Carracedo, M. Lamas, A. Fernández-Ferreiro
{"title":"Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study","authors":"S. Blanco Dorado, O. Maroñas, Ana Latorre-Pellicer, Teresa Rodríguez Jato, Ana López-Vizcaíno, Áurea María Gómez Márquez, B. Bardán García, Dolores Belles Medall, G. Barbeito Castiñeiras, M. L. Pérez Del Molino Bernal, M. Campos‐Toimil, F. O. Otero Espinar, Andrés Blanco Hortas, G. Durán Piñeiro, I. Zarra Ferro, Á. Carracedo, M. Lamas, A. Fernández-Ferreiro","doi":"10.1002/phar.2351","DOIUrl":"https://doi.org/10.1002/phar.2351","url":null,"abstract":"Voriconazole, a first‐line agent for the treatment of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to achieve therapeutic voriconazole trough concentrations, with a consequently increased risk of therapeutic failure.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82951278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Naloxone Administration by Untrained Community Members 未经培训的社区成员给纳洛酮
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-11-28 DOI: 10.1002/phar.2352
W. Eggleston, V. Calleo, Martin Kim, S. Wojcik
{"title":"Naloxone Administration by Untrained Community Members","authors":"W. Eggleston, V. Calleo, Martin Kim, S. Wojcik","doi":"10.1002/phar.2352","DOIUrl":"https://doi.org/10.1002/phar.2352","url":null,"abstract":"Access to naloxone is a priority for reducing opioid deaths. Although community members who complete naloxone training are able to administer nasal naloxone successfully and rapidly, little is known about the ability of community members to administer naloxone without training. The objective of this study was to assess the ability of untrained individuals to administer naloxone successfully in a simulated opioid overdose setting.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77366033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation 房颤患者的口服抗凝处方趋势、概况使用和依从性决定因素
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-11-22 DOI: 10.1002/phar.2350
S. Perreault, S. de Denus, B. White-Guay, R. Cote, M. Schnitzer, M. Dubé, M. Dorais, J. Tardif
{"title":"Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation","authors":"S. Perreault, S. de Denus, B. White-Guay, R. Cote, M. Schnitzer, M. Dubé, M. Dorais, J. Tardif","doi":"10.1002/phar.2350","DOIUrl":"https://doi.org/10.1002/phar.2350","url":null,"abstract":"Data on oral anticoagulant (OAC) uptake and pattern of use are limited. Real‐life data in patients with atrial fibrillation (AF) are important for understanding patient exposure. A cohort study of new OAC users was built to assess trends of drug use from 2011 to 2017, persistence rate, switching rate, adherence level, and predictors of adherence.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75886954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 80
Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation 体外膜氧合过程中两性霉素B和异戊康唑脂质体药代动力学和剂量的改变
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-11-19 DOI: 10.1002/phar.2348
Yanjun Zhao, T. Seelhammer, E. Barreto, John W. Wilson
{"title":"Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation","authors":"Yanjun Zhao, T. Seelhammer, E. Barreto, John W. Wilson","doi":"10.1002/phar.2348","DOIUrl":"https://doi.org/10.1002/phar.2348","url":null,"abstract":"Drug pharmacokinetics may be significantly altered in patients receiving extracorporeal membrane oxygenation (ECMO). Ensuring the optimized effective dosing of antimicrobials on ECMO remains a challenge. To date, limited data are available regarding the optimal use of amphotericin and triazoles during ECMO. We report a case of altered pharmacokinetics, insufficient liposomal amphotericin B and isavuconazole levels, and the need for escalated doses during ECMO in a patient with severe acute respiratory distress syndrome secondary to pulmonary blastomycosis. A 2‐fold increase in the standard total daily dose of both drugs was necessary to overcome low serum concentrations thought to be secondary to drug loss from ECMO circuit sequestration. These findings have important implications for optimizing antimicrobial therapy in patients receiving ECMO to maximize therapeutic efficacy. The use of therapeutic drug monitoring for patients receiving antimicrobial therapy with concurrent ECMO may facilitate appropriate drug dosing to achieve adequate serum concentrations and optimize favorable patient outcomes. Further studies exploring antimicrobial pharmacokinetics during ECMO are needed to inform dosing recommendations in critically ill patients.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88719130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 35
Pharmacokinetics of Basiliximab for the Prevention of Graft‐versus‐Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal‐Intensity Cyclophosphamide and Fludarabine 巴利昔单抗预防低剂量环磷酰胺和氟达拉滨造血细胞移植患者移植物抗宿主病的药代动力学研究
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-11-19 DOI: 10.1002/phar.2347
J. Podichetty, B. Brinda, R. Nelson, Alissa H. Karr, N. Prasad, S. Quinney, Susanna Foxworthy Scott, P. Kiel
{"title":"Pharmacokinetics of Basiliximab for the Prevention of Graft‐versus‐Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal‐Intensity Cyclophosphamide and Fludarabine","authors":"J. Podichetty, B. Brinda, R. Nelson, Alissa H. Karr, N. Prasad, S. Quinney, Susanna Foxworthy Scott, P. Kiel","doi":"10.1002/phar.2347","DOIUrl":"https://doi.org/10.1002/phar.2347","url":null,"abstract":"Basiliximab is an immunosuppressive monoclonal antibody used for rejection prevention following solid organ transplantation; the pharmacokinetics (PK) of basiliximab in this setting are known. Basiliximab may also be used for prophylaxis and treatment of graft‐versus‐host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT); however, the PK of basiliximab in this setting are not known. Clinical transplant providers expect variation in the volume of distribution and clearance after nonmyeloablative allogeneic transplantation (NMAT) compared with solid organ transplantation. Blood loss, organ site–specific antibody accumulation, and differences in blood product use during the two transplantation approaches may generate differences in basiliximab PK. Therefore, the objective of this study was to describe the PK of basiliximab after its addition to a minimally intense NMAT regimen, in conjunction with cyclosporine, for GVHD prophylaxis in patients with hematologic malignancies.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74824500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Genetic Polymorphisms in Antioxidant Enzymes Modulate the Susceptibility of Idiosyncratic Antituberculous Drug‐Induced Liver Injury and Treatment Outcomes in Patients with Tuberculosis 抗氧化酶的遗传多态性调节特异性抗结核药物诱导的结核病患者肝损伤的易感性和治疗结果
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-11-19 DOI: 10.1002/phar.2349
Q. Sun, W. Sha, Haipeng Liu, Peng Wang, Zhi-bin Liu, Wen Sun, He-ping Xiao
{"title":"Genetic Polymorphisms in Antioxidant Enzymes Modulate the Susceptibility of Idiosyncratic Antituberculous Drug‐Induced Liver Injury and Treatment Outcomes in Patients with Tuberculosis","authors":"Q. Sun, W. Sha, Haipeng Liu, Peng Wang, Zhi-bin Liu, Wen Sun, He-ping Xiao","doi":"10.1002/phar.2349","DOIUrl":"https://doi.org/10.1002/phar.2349","url":null,"abstract":"The pathogenic mechanism of antituberculous drug‐induced liver injury (ATDILI) is associated with antioxidant enzymes. The objective of the present study was to investigate the associations of ATDILI susceptibility with genetic polymorphisms of antioxidant enzyme genes including nitric oxide synthase 2 (NOS2), thioredoxin reductase 1 (TXNRD1), superoxide dismutase 2 (SOD2), BTB domain and CNC homolog 1 (BACH1), and MAF bZIP transcription factor K (MAFK).","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76008305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock 抗利尿激素血浆浓度与感染性休克外源性抗利尿激素的血流动力学反应无关
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2019-11-09 DOI: 10.1002/phar.2346
Jason Yerke, Gretchen L. Sacha, R. Scheraga, D. Culver, Susamma Abraham, Heather Torbic, S. Lam, Mahmoud A. Ammar, M. Olman, S. Bauer
{"title":"Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock","authors":"Jason Yerke, Gretchen L. Sacha, R. Scheraga, D. Culver, Susamma Abraham, Heather Torbic, S. Lam, Mahmoud A. Ammar, M. Olman, S. Bauer","doi":"10.1002/phar.2346","DOIUrl":"https://doi.org/10.1002/phar.2346","url":null,"abstract":"Positive hemodynamic response to vasopressin after 6 hours of infusion was independently associated with lower mortality in a previous retrospective study of patients with septic shock. However, factors previously associated with higher plasma vasopressin concentration were not associated with response, and the relationship between plasma vasopressin concentration and hemodynamic response has not been evaluated.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83232332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信